📈 Jumpstart Signal Watchlist — July 23, 2026

🏢 What they do: DiamondRock Hospitality Company (DRH) is a self-advised real estate investment trust (REIT) that owns a portfolio of approximately 35-36 premium hotels and resorts with about 9,600 rooms, concentrated in U.S. gateway markets and leisure destinations.
- 🎯 Current $12.67 is 2% below 3yr high $12.97 · ⏳ SMA200 $9.81 (current price $12.67 is above) · 💰 Market Cap $2.6B
- DRH shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (10.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 75% (>20%); Low LT D/E 0.76 (<1.0); PEG ratio 0.36 (<1.5).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 64 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Diamondrock Hospitality stock hits 52-week high at $12.47 — Investing.com.
🤖 The article says DRH reached a 52-week high and notes prior first-quarter 2026 earnings beat expectations, along with a property sale for $33.0 million. Those are favorable signals for the stock because they reflect strong share momentum and value-creating company actions.
⚪️ DiamondRock Hospitality Company (NYSE:DRH) Given Consensus Recommendation of "Hold" by Brokerages — MarketBeat.
🤖 This is a recent analyst-consensus update rather than a company operating update. The stock is rated Hold overall, which suggests mixed sentiment and limited immediate directional impact.
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: Sotera Health is a global healthcare services company that provides sterilization solutions, laboratory testing, and technical advisory services to help ensure medical and pharmaceutical products are safe for use.
- 🎯 Current $17.49 is 10% below 3yr high $19.35 · ⏳ SMA200 $16.43 (current price $17.49 is above) · 💰 Market Cap $5.0B
- SHC shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 280% (>20%); ROE 19% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.15 (<1.5).
⏰ Entry (E): 3/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 53 in healthy mid-range
📢 Sentiment (S): 7/10
- 🗞️ News sentiment is positive.
✅ Sotera Health Company (NASDAQ:SHC) Given Average Rating of Moderate Buy by Brokerages — MarketBeat.
🤖 The analyst consensus is described as "Moderate Buy," with 8 of 11 firms recommending buy and an average price target of $20.25. That implies favorable sentiment relative to the recent trading price.
⚪️ Sotera Health Announces Second-Quarter 2026 Earnings Release Date — Yahoo Finance.
🤖 This is a bare earnings-date announcement with no results, guidance, or analyst opinion, so it is not meaningful fundamental news for $SHC. It does not change the stock outlook by itself.
⚪️ Sotera Health Company $SHC Shares Purchased by State of Wyoming — MarketBeat.
🤖 The article reports a disclosed share purchase by an institutional holder, which is generally a mild signal but not enough to be clearly bullish or bearish on its own. The available snippet does not indicate a major operational or financial change for Sotera Health.
🍭 Bonus (B): 0/10 — Misc Health & Allied Services

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $55.65 is 2% below 3yr high $57.10 · ⏳ SMA200 $45.12 (current price $55.65 is above) · 💰 Market Cap $14.1B
- EXEL shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (9.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 44% (>20%); ROE 43% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Exelixis Inc stock hits all-time high at 56.22 USD By Investing.com — Investing.com.
🤖 The article says EXEL reached an all-time high and notes strong year-to-date and six-month gains, which reflects bullish market sentiment. It also cites analyst updates and trial-related developments that the piece frames as supporting investor confidence.
✅ EXEL Stock Soars 26.8% in Three Months — Yahoo Finance / Zacks.
🤖 The article highlights substantial recent share-price outperformance versus the industry and the broader market. It is framed positively by the author, who also points to Zanzalintinib as a key growth driver.
⚪️ Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026 — Business Wire.
🤖 This is a bare earnings-date announcement with no results, guidance, or analyst commentary, so it does not provide a direct price catalyst. It is included only as a publication in the date range, but the content itself is neutral and limited.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Progyny, Inc. is a benefits management company that provides employer-sponsored fertility, family-building, and women’s health benefits. Its services include access to a network of fertility specialists, concierge care support, and an integrated pharmacy benefits program called Progyny Rx for fertility medications.
- 🎯 Current $30.70 is 28% below 3yr high $42.90 · ⏳ SMA200 $22.98 (current price $30.70 is above) · 💰 Market Cap $2.4B
- PGNY shows decent technicals supported by positive sentiment.

💎 Quality (Q): 50/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 71% (>20%); ROE 15% (>15%); Low LT D/E 0.00 (<1.0); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA50 (11.4%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (58) — BEARISH
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Progyny (PGNY) Stock Is Up, What You Need To Know — Yahoo Finance.
🤖 KeyBanc raised its price target to $35 from $30 and kept an Overweight rating, citing expectations for a strong earnings report and higher future guidance. The article also notes additional bullish analyst actions from Truist and Canaccord, which supports a positive stock-price view.
✅ Progyny, Inc. (NASDAQ:PGNY) Receives Average Recommendation of "Moderate Buy" from Analysts — MarketBeat.
🤖 The article reports a consensus analyst rating of Moderate Buy with 10 buy ratings and 3 hold ratings, plus an average price target around $30.09. It also highlights a recent earnings beat and a $200 million buyback, both of which are supportive for the stock.
✅ Progyny (PGNY) Q1 Earnings and Revenues Beat Estimates — Zacks.
🤖 Progyny reported quarterly EPS of $0.50, above the $0.44 consensus estimate, which is typically positive for investor sentiment. Earnings beats can support the stock by reinforcing confidence in execution and valuation.
🍭 Bonus (B): 0/10 — Misc Health & Allied Services

🏢 What they do: BrightSpring Health Services (BTSG) is a leading provider of comprehensive home and community-based health services, including clinical, nonclinical, pharmacy, and ancillary care, to complex populations across all ages and skill levels. It operates as the parent company of brands focused on specialized care in home and community settings, emphasizing quality outcomes for people with complex needs.
- 🎯 Current $69.84 is 4% below 3yr high $72.56 · ⏳ SMA200 $44.60 (current price $69.84 is above) · 💰 Market Cap $13.5B
- BTSG shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 Low drawdown (9.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 379% (>20%); Revenue growth 26% (>15%); ROE 16% (>15%).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ מניית BTSG מגיעה לשיא כל הזמנים של $70.99 — Investing.com.
🤖 הכתבה מציינת שהמניה הגיעה לשיא כל הזמנים ונסחרת קרוב מאוד לשיא של 52 השבועות, מה שמעיד על מומנטום חיובי חזק עבור $BTSG. היא גם מתארת עלייה שנתית חדה, אך אינה מוסיפה מידע מהותי חדש על תוצאות עסקיות או הנחיות.
🍭 Bonus (B): 0/10 — Home Health Care Services

🏢 What they do: A global provider of high-performance electronic components, including advanced micro-acoustic microphones, balanced armature speakers, capacitors, and radio frequency (RF) filtering products.
- 🎯 Current $38.81 is 9% below 3yr high $42.80 · ⏳ SMA200 $28.20 (current price $38.81 is above) · 💰 Market Cap $3.3B
- KN shows decent technicals supported by positive sentiment.

💎 Quality (Q): 46/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 650% (>20%); Low LT D/E 0.15 (<1.0); PEG ratio 0.09 (<1.5).
⏰ Entry (E): 7/20
- 🔔 High-vol breakout (rank=1.13x, quality=0.74)
- 🔔 Fresh SMA50 breakout
- ⚠️ SMA20/SMA50 bearish crossover
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Knowles Reports Q2 2026 Financial Results and Provides Outlook for Q3 2026 — Business Wire.
🤖 Knowles reported second-quarter 2026 results and provided Q3 and full-year outlook, which were stronger than expected based on the companion coverage. The article is positive for $KN because it reflects a fresh earnings release with improved guidance rather than a mere date announcement.
✅ Knowles Q2 2026 slides: Precision Devices revenue surges 25% — Investing.com.
🤖 The report says Knowles beat earnings and revenue expectations, with revenue up 14.3% year over year and adjusted EPS up 37.5%. It also notes raised 2026 expectations, which is typically supportive for the stock.
✅ Knowles (NYSE:KN) Releases Earnings Results, Beats Estimates By $0.03 EPS — MarketBeat.
🤖 Knowles beat consensus EPS and revenue estimates and raised Q3 2026 guidance. The market reacted favorably, with shares rising after the release, which makes this bullish for $KN.
🍭 Bonus (B): 0/10 — Household Audio & Video

🏢 What they do: Aramark is a global provider of outsourced food services, facilities management, and uniform services to clients in education, healthcare, business, sports, leisure, and corrections sectors .
- 🎯 Current $57.00 is 2% below 3yr high $58.15 · ⏳ SMA200 $43.49 (current price $57.00 is above) · 💰 Market Cap $15.0B
- ARMK shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (7.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 65% (>20%); Low LT D/E 0.00 (<1.0); PEG ratio 0.65 (<1.5).
⏰ Entry (E): 3/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 61 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Oppenheimer raises Aramark stock price target on strong revenue growth — Investing.com.
🤖 Oppenheimer lifted its price target on ARMK while keeping an Outperform rating, citing strong revenue growth and expanding data center opportunities. The article also notes additional bullish views from Truist and Stifel, which is supportive for the stock.
✅ Aramark (NYSE:ARMK) Given Consensus Recommendation of Moderate Buy by Analysts — MarketBeat.
🤖 This article reports that ARMK has a consensus analyst rating of Moderate Buy, with 11 of 13 covering firms rating it a buy and an average 12-month target price around $58.29. That level of analyst support is generally positive for sentiment.
⚪️ Financial Group Inc. Grows Position in Aramark $ARMK — MarketBeat.
🤖 The piece focuses on an institutional position increase and repeats analyst-rating data, rather than providing new operating news or company-specific developments. It is mildly supportive but not a direct catalyst for the stock.
⚪️ Hsbc Holdings PLC Has $8.69 Million Stock Holdings in Aramark $ARMK — MarketBeat.
🤖 This article centers on a large institutional holding and again cites the stock’s Moderate Buy consensus rating. It does not contain a meaningful new company-specific development, so the impact on ARMK is limited.
🍭 Bonus (B): 0/10 — Restaurants